RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.